GlassScriptPhysician profile
Alfred L Laborde
NPI 1114924396
$2,242.43
in general payments reported to CMS, 2019-2025
13 companies · $713 in 2025
The $713 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $14.45 · 2021: $11.65 · 2022: $554 · 2023: $607 · 2024: $20.24 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $641.03 | 2022-2025 | Gore Viabahn Vbx Balloon Expandable Endo |
| Medtronic, INC. | $509.13 | 2022-2025 | Endurant Iis |
| Inari Medical, INC. | $197.84 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Endologix LLC | $149.63 | 2025 | Endocross Device, Torus Stent Graft System |
| Penumbra, INC. | $148.35 | 2025 | Penumbra System |
| Boston Scientific Corporation | $116.22 | 2019 | |
| Getinge USA Sales, LLC | $112.06 | 2019 | |
| Lemaitre Vascular, INC. | $103.46 | 2023-2025 | Restoreflow, Artegraft Vascular Graft |
| Tactile Systems Technology INC | $101.86 | 2019-2023 | Flexitouch Plus, Entre Plus |
| Organogenesis INC. | $87.42 | 2019-2023 | Puraply |
| Acera Surgical, INC. | $32.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.56 | 2019-2021 | |
| Avinger INC. | $14.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Laborde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.